Park Changwoo, Kim Kwan Woo, Park Dongju, Hassan Zohaib Ul, Park Edmond Changkyun, Lee Chang-Seop, Rahman Md Tazikur, Yi Hana, Kim Seil
Microbiological Analysis Team, Group for Biometrology, Korea Research Institute of Standards and Science (KRISS), Daejeon, South Korea.
Convergent Research Center for Emerging Virus Infection, Korea Research Institute of Chemical Technology (KRICT), Daejeon, South Korea.
Front Microbiol. 2022 Aug 17;13:876085. doi: 10.3389/fmicb.2022.876085. eCollection 2022.
As SARS-CoV-2 variants of concern emerged, the genome sequencing of SARS-CoV-2 strains became more important. In this study, SARS-CoV-2 was sequenced using amplicon-based genome sequencing with MinION. The primer panel used in this study consisted of only 11 primer panels and the size of the amplicons was approximately 3 kb. Full genome sequences were obtained with a hundred copies of the SARS-CoV-2 genome, and 92.33% and 75.39% of the genome sequences were obtained with 10 copies of the SARS-CoV-2 genome. The few differences in nucleotide sequences originated from mutations in laboratory cultures and/or mixed nucleotide sequences. The quantification of the SARS-CoV-2 genomic RNA was done using RT-ddPCR methods, and the level of LoD indicated that this sequencing method can be used for any RT-qPCR positive clinical sample. The sequencing results of the SARS-CoV-2 variants and clinical samples showed that our methods were very reliable. The genome sequences of five individual clinical samples were almost identical, and the analysis of the sequence variance showed that most of these nucleotide substitutions were observed in the genome sequences of the other clinical samples, indicating this amplicon-based whole-genome sequencing method can be used in various clinical fields.
随着新冠病毒(SARS-CoV-2)关注变异株的出现,SARS-CoV-2毒株的基因组测序变得愈发重要。在本研究中,使用基于扩增子的基因组测序技术结合MinION对SARS-CoV-2进行测序。本研究中使用的引物组仅由11个引物组组成,扩增子大小约为3 kb。使用一百份SARS-CoV-2基因组获得了完整基因组序列,使用十份SARS-CoV-2基因组获得了92.33%和75.39%的基因组序列。核苷酸序列中的少量差异源于实验室培养中的突变和/或混合核苷酸序列。使用RT-ddPCR方法对SARS-CoV-2基因组RNA进行定量,检测限水平表明该测序方法可用于任何RT-qPCR阳性临床样本。SARS-CoV-2变异株和临床样本的测序结果表明我们的方法非常可靠。五个个体临床样本的基因组序列几乎相同,序列变异分析表明,这些核苷酸替换中的大多数在其他临床样本的基因组序列中也有观察到,这表明这种基于扩增子的全基因组测序方法可用于各种临床领域。